Trial Evaluating Cardiovascular Outcomes With Sitagliptin

Home page

TECOS is a double-blind randomized, placebo controlled, multi-national trial in patients with Type 2 Diabetes coordinated by the Duke Clinical Research Institute (DCRI) and the University of Oxford Diabetes Trial Unit (DTU).

It is being conducted in around 40 countries, across Australasia, Asia, Europe, North America, South America, India and South Africa, and commenced in 2008. TECOS aims to compare the impact of adding sitagliptin as part of usual care versus usual care without sitagliptin on cardiovascular outcome. TECOS is an event driven trial of over 14,000 patients that will continue until 1,300 confirmed cardiovascular events have accumulated.

Co-Chair: Professor Robert Califf (Duke University, US)
Co-Chair: Professor Rury Holman (The University of Oxford, UK)
Clinical Lead (Durham, USA): Dr Jennifer Green
Clinical Lead (Oxford, UK): Dr Angelyn Bethel
Project Manager (Durham, USA): Tyrus Rorick
Project Manager (Oxford, UK): Jo Milton

Clinical trials.gov identifier: NCT00790205

News

Show all

2013

March

The Global Reach of TECOS

TECOS is funded by Merck in an academic collaboration with the Duke Clinical Research Institute and the Diabetes Trials Unit.